Get the Stockscreener App
4.51
5.85%
-0.28
After Hours:
4.51
Relay Therapeutics Inc Stock (RLAY) Latest News
Healthy Upside Potential: Relay Therapeutics Inc (RLAY) - SETE News
BlackRock, Inc. Expands Stake in Relay Therapeutics Inc with Sig - GuruFocus.com
Jefferies Upgrades Relay Therapeutics Inc (RLAY) to a Buy from a Hold - Knox Daily
SG Americas Securities LLC Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of “Moderate Buy” from Brokerages - ETF Daily News
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
How should investors view Relay Therapeutics Inc (RLAY)? - US Post News
Is Relay Therapeutics Inc (NASDAQ: RLAY) Stock Worth Investing In for High Returns? - Marketing Sentinel
Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 17,250 Shares - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 20,791 Shares - MarketBeat
Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells 36,036 Shares of Stock - MarketBeat
Relay Therapeutics Insider Sold Shares Worth $268,339, According to a Recent SEC Filing - Marketscreener.com
Relay Therapeutics Inc (RLAY) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Relay Therapeutics CEO Sanjiv Patel sells $1.76 million in stock - MSN
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down on Insider Selling - Defense World
Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells $600,000.00 in Stock - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Shares Down 6%Here's What Happened - MarketBeat
Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays’ $17 Price Target - MSN
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Down After Insider Selling - MarketBeat
Relay Therapeutics CEO Sanjiv Patel sells $1.76 million in stock By Investing.com - Investing.com UK
Relay Therapeutics (NASDAQ:RLAY) Trading 6.8% HigherHere's Why - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week LowShould You Sell? - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest Update - MarketBeat
Relay Therapeutics' SWOT analysis: stock poised for growth amid fierce competition - MSN
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8%Time to Sell? - MarketBeat
We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate - Yahoo Finance
Relay Therapeutics’ (RLAY) Buy Rating Reiterated at HC Wainwright - Defense World
Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week LowShould You Sell? - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Given "Buy" Rating at HC Wainwright - MarketBeat
Lilly Pays Up To $2.5bn For Scorpion, Will Put Big Pharma Muscle Behind PI3Kα Inhibitor - Citeline News & Insights
Relay Therapeutics Highlights Progress at Healthcare Conference - TipRanks
Barclays PLC Grows Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Barclays PLC Purchases 136,541 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws - MSN
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Relay Therapeutics stock hits 52-week low at $4 By Investing.com - Investing.com South Africa
Relay Therapeutics (NASDAQ:RLAY) Hits New 12-Month LowShould You Sell? - MarketBeat
Relay Therapeutics stock hits 52-week low at $4 - Investing.com India
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws (LLY:NYSE) - Seeking Alpha
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):